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Cancer cachexia describes a syndrome of progressive 
weight loss due to muscle wasting with or without the 
loss of adipose tissue, anorexia, and abnormal meta-
bolism in the presence of underlying cancer [1]. It 
cannot be reversed by conventional nutritional support 
and leads to progressive functional impairment [1, 2]. 
Nearly half of all cancer patients are faced with 
cachexia in the course of their disease, and it is the 
cause of death in up to 20 percent [3-5]. Catabolic 
cytokines and patient-related factors such as age are key 
pathogenic mechanisms underlying cancer cachexia [6-
8]. Catabolic pro-inflammatory cytokines associated 
with cancer cachexia include interleukin-6 (IL-6), 
interleukin-1 beta (IL-1B), tumor necrosis factor alpha 
(TNF-α), and interferon gamma (IFN-γ) [7, 9].  
 
Particularly IL-6 is found highly upregulated in the final 
months preceding death [10]. Treatment aimed at 
reducing the synthesis of pro-inflammatory cytokines or 
blocking their action may, therefore, contribute to 
improved physical performance and quality of life [11-
13].  
 
Besides novel pharmaceutical strategies to limit the 
activity of catabolic cytokines in cancer cachexia, 
dietary interventions have sparked great interest [11, 13-
19]. Thus far dietary interventions for the treatment of 
cancer cachexia have evaluated supplementation 
therapy. Long-chain omega-3 fatty acid eicosapentae-
noic acid (EPA) is one of the most frequently 
investigated supplements. Systematic reviews of the 
literature published since have been unable to support 
clinical application of EPA for the treatment of cancer 
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allocated as C26  tumor‐bearing  (TB) + ad  libitum  food  intake  (dietary  reference  intake  [DRI]), TB CR, non‐TB
(NTB) CR, or NTB matched  intake  (MI). TB groups were  inoculated  subcutaneously with 0.5x106 C26  cells 14
days after initiating CR. Bodyweight, food intake, and grip‐strength were recorded periodically. Gastrocnemius





Expression  of  myogenin  was  increased  in  CR  groups.  In  conclusion,  caloric  restriction  limits  loss  of  muscle
strength but has no impact on muscle mass despite significant  loss of body weight in an experimental cancer‐
associated cachexia model. 
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cachexia [18, 20]. Only smaller studies initially reported 
to limit weight loss in cancer patients [21].  In contrast 
to this, β-hydroxy-β-methylbutyrate (HMB), a leucine 
metabolite, and quercetin have been found to limit 
experimental muscle wasting in vivo [14-16] as well as 
in a clinical trial following a 24-week supplementation 
program [22]. Similarly, another study found a strong 
trend towards the preservation of muscle mass in 
advanced cancer patients following 8 weeks of HMB 
supplementation. [23]. Although counterintuitive, 
caloric restriction (CR) may elicit similar effects. The 
beneficial effects of CR on healthspan and longevity 
have been thoroughly established in model organisms, 
and include reduced incidence of cancer, cardiovascular 
disease, and increased oxidative stress resistance [24-
31]. Experiments in our own laboratory have shown that 
two weeks of 30% CR improves insulin sensitivity, 
increased insulin/insulin-like growth factor 1 signaling, 
increases expression of markers of antioxidant defense, 
and reduces expression of markers of inflammation in 
mice [29]. In rodents and nonhuman primates, CR was 
able to limit sarcopenia, i.e. the age-related loss of 
muscle mass [32-35]. Similarly as in cancer cachexia, 
catabolic pro-inflammatory cytokines are suggested to 
play an important role in the development of sarcopenia 































Therefore, we questioned whether CR could limit 
muscle wasting and loss of muscle function in an 
experimental cancer cachexia model and we examined 
the impact of CR on body weight, muscle weight, and 
grip-strength. In addition, the mRNA expression levels 
of skeletal muscle catabolic E3 ubiquitin ligases and 




To study the effects of 30% caloric restriction forty 
male CD2F1 mice were allocated to four groups. Mice 
allocated to be C26 tumor-bearing (TB) animals with ad 
libitum access to chow were used as dietary reference 
intake (DRI) for all other mice in this experiment, i.e. 
C26 TB mice on a 30% caloric restriction (CR) diet; 
non-tumor bearing (NTB) mice with matched intake to 
the TB-DRI group (MI); NTB mice on a 30% caloric 
restriction diet.  
 
Following initiation of 30% CR, a rapid but similar 
decline in body weight was observed in both CR groups 
(NTB-CR and TB 30% CR) (Figure 1). This loss of 
bodyweight was most apparent in the first week, prior to 
inoculation of the C26 adenocarcinoma cells. Con-



































tumor‐bearing groups. The vertical bars  indicate daily measurements of body weight, ranging  from day 0 to 35,  for each specified
group. Bodyweight was normalized to each animal’s body weight on day 0 and  is expressed as the percental difference. Following
initiation of 30% CR a rapid decline  in body weight was observed prior to tumor  inoculation,  ‐10.5% for C26 TB 30% CR mice and  ‐
10.6%  for   NTB 30% CR mice  (p < 0.001  for both groups compared  to C26 TB DRI). Following  tumor  inoculation, C26 TB DRI mice






























30% CR alone. Mice allocated to the NTB MI group 
had access to an equal amount of food per cage as 
consumed the day prior by C26 TB DRI mice. Despite 
this, the NTBI MI group consumed significantly less 
than the TB DRI mice during the first 7 days of the 
experiment, i.e. prior to actual tumor inoculation 
(Figure 2). The mean intake of C26 TB DRI mice was 
3.7 g versus 3.4 g in NTB MI mice (p = 0.03). This 
difference in food intake between the NTB MI and C26 
TB DRI groups was associated with a lower maximum 
increase in bodyweight. At tumor inoculation, mean 
body weight in TB 30% CR mice was 88.6% of initial 
body weight compared with 106.9% in the TB DRI 
mice. Following tumor inoculation, mice in the TB DRI 
group gained bodyweight until 28 days after the start of 
the experiment. From day 28 until sacrifice at day 35, 
animals lost 10.6% of initial body weight (p = 0.01). 
This was associated with a decrease in food intake from 
3.8 g to 2.9 g (p = 0.0002). Consequently, NTB MI 
mice too experienced a loss of 6.4% in body weight in 
these final days of the experiment (p=0.002). Mice in 
the TB 30% CR group had a stable bodyweight 
following tumor inoculation, and no further decrease in 
body weight was observed (p = 0.186). Mice in the 
NTB 30% CR group lost 7.6% in mean body weight in 
the final days of the experiment (p = 0.004). This 
difference may, in part but not exclusively, be attributed 
to tumor weight increase in the TB 30% CR group. 
 
A reduction in grip-strength was observed throughout 























































final mean loss of grip-strength was 7.9% when 
compared to starting grip-strength. TB 30% CR mice, 
Figure 2. Daily food intake throughout the experiment. Grouped histograms depicting the mean daily food intake per group
in C26 tumor‐bearing (TB) male CD2F1 mice with ad libitum access to chow (dietary reference intake [DRI], n = 10); C26 TB mice on




Figure  3.  Relative  grip‐strength  at  the  end  of  the
experiment. Bar graphs depicting the mean ± SEM for final grip‐
strength  normalized  to  starting  grip‐strength  in  C26  tumor‐
bearing  (TB) male  CD2F1 mice with  ad  libitum  access  to  chow
(dietary  reference  intake  [DRI], n = 10); C26  TB mice on  a 30%
caloric restriction (CR, n = 10) diet; non‐tumor bearing (NTB) mice
with  matched  intake  (MI,  n  =  10);  NTB mice  on  a  30%  caloric
restriction (n = 10). Multiple group comparisons were done by one‐
way  ANOVA  with  a  Bonferroni’s  post  hoc  test.  All  groups were
compared against TB – DRI mice. Asterisk brackets are displayed for
significant results only. * p < 0.05 ** p < 0.01 *** p < 0.001. 
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on the other hand, experienced an increase of 15.4% in 
grip-strength throughout the experiment. This difference 
was significant in comparison to the TB DRI mice (p = 
0.02). NTB mice, both NTB MI and NTB 30% CR, 
experienced the greatest increase in grip-strength, which 
was 31.7% (p < 0.001) and 28.6% (p = 0.0002) 
respectively at the end of the experiment. 
 
All animals were sacrificed at 21 days following tumor 
inoculation, i.e. 35 days after onset of the experiment. 
At sacrifice, the final decrease in bodyweight was 
greatest in TB 30% CR and NTB 30% CR mice, 10.5% 
and 14.0% respectively (Figure 4A). As expected, NTB 










































DRI mice experienced a rapid decline in body weight in 
the final days preceding sacrifice by 10.6%. Tumor 
mass increased until day 21, when resected mean tumor 
weight was 662 ± 316 mg in TB DRI mice versus 480 ± 
249 mg in TB 30% CR mice. This trend towards 
reduced tumor growth in CR mice was not significant (p 
= 0.17) (Figure 4B). Furthermore, no association bet-
ween tumor weight and body weight loss was observed. 
Directly following sacrifice, the gastrocnemius and 
tibialis anterior muscles were resected and weighed. 
Mean gastrocnemius muscle weight in NTB MI mice 
was 158.3 ± 18.3 mg versus 128.7 ± 25.3 mg in TB DRI 
mice, p = 0.008 (Figure 4C). Mean gastrocnemius 
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15.5 mg, comparable to C26 TB DRI mice (p > 0.99). 
Similarly, mean gastrocnemius muscle weights for NTB 
30% CR mice were 132.5 ± 15.4 mg, comparable to 
C26 TB DRI mice (p > 0.99). Mean tibialis anterior 
muscle weight in NTB MI mice was 48.9 ± 3.4 mg 
versus 42.1 ± 8.5 mg in the C26 TB DRI mice (p = 
0.08) (Figure 4D). Mean tibialis anterior muscle 
weights for C26 TB 30% CR mice were 42.6 ± 5.4 mg, 
comparable to C26 TB DRI mice (p > 0.99). Similarly, 
mean tibialis anterior muscle weights for NTB 30% CR 
mice were 40.0 ± 4.9 mg, comparable to C26 TB DRI 
mice (p > 0.99).  
 
Skeletal muscle E3 ubiquitin ligases and myogenic 
regulatory factors mRNA expression profiles were 
determined in gastrocnemius muscle samples. A sub-
stantial, non-significant difference in E3 ubiquitin ligase 
atrogin-1 expression was observed between C26 TB 
DRI and NTB MI (Figure 5A). No difference was 
observed between C26 TB DRI, C26 TB 30% CR and 
NTB 30% CR. Expression of the second E3 ubiquitin 
ligase MuRF1 and myogenic regulatory factor MyoD 
were comparable between all four groups (Figure 5B, 
5C). Finally, and perhaps most interesting, there was 
increased expression of the myogenic regulatory factor 
myogenin in the NTB 30% CR group (p = 0.002) as 
well as a substantial, non-significant elevation in the TB 




Cancer-associated cachexia is a common finding in 
patients affected by numerous types of malignancies 























dalities to halt or reverse this process of muscle wasting.  
Previously it was shown that caloric restriction may 
decrease age-related sarcopenia [32-34]. Our study 
investigated whether caloric restriction might protect 
against muscle wasting and loss of muscle function. 
Although counterintuitive, our findings show that in the 
C26 cancer cachexia model, caloric restriction had no 
impact on muscle wasting when compared to ad libitum 
fed TB mice. Moreover, the mRNA expression of E3 
ubiquitin ligases MuRF1 and Atrogin-1 expression was 
unaffected by 30% caloric restriction. This suggests a  
protective mechanism by which CR prevents aggravated 
muscle wasting. This was also reflected in grip-strength. 
The final grip-strength in the TB 30% CR group was 
greater than the final grip-strength in TB DRI mice. 
Nonetheless, this grip-strength was still decreased 
compared to both NTB MI as well as NTB 30% CR 
mice. CR alone had no impact on grip strength in non-
tumor-bearing mice. Similar findings have been 
previously reported [40]. Discrepancies between muscle 
mass and muscle strength have also been noted in 
human populations [41-43]. Taken together, these 
findings show a limited protective effect on the 
functional outcome of CR in tumor-bearing mice, which 
is not powerful enough to prevent loss of muscle 
strength. This protective effect may be attributed to the 
enhanced expression of myogenin in mice on a 30% 
caloric restriction diet.  
 
Similar effects of myogenin have previously been 
described following myogenin gene transfer in an ALS 
model [44]. In that study, myogenin gene transfer lead 
to increased rotarod performance, whilst the body-
























Figure  5.  mRNA  expression  levels  in  cachectic  muscle.  Bar  graphs  depicting  the  mean  ±  SEM  mRNA  expression  levels  in
gastrocnemius muscle of  (A) Atrogin‐1,  (B) MuRF1,  (C) MyoD and  (D) Myogenin  in C26  tumor‐bearing  (TB) male CD2F1 mice with ad
libitum access  to chow  (dietary  reference  intake  [DRI], n = 10); C26 TB mice on a 30% caloric  restriction  (CR, n = 10) diet; non‐tumor
bearing (NTB) mice with matched  intake (MI, n = 10); NTB mice on a 30% caloric restriction (n = 10). Multiple group comparisons were
done by one‐way ANOVA with  a Bonferroni’s post hoc  test. All  groups were  compared  against  TB  – DRI mice. Asterisk brackets  are
displayed for significant results only. * p < 0.05 ** p < 0.01 *** p < 0.001. 
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In addition, mice allocated to receive CR, both tumor-
bearing and non-tumor bearing, showed enhanced 
activity throughout the experiment, e.g. increased run-
ning and climbing, as well as being found frequently 
hanging from the top of the cage. Although we did not 
quantify these findings, similar results have been 
reported in an age-related sarcopenia caloric restriction 
rodent model [40] .The increased activity of animals on 
CR may have contributed to the preservation of grip-
strength as well as to myogenin upregulation.  
 
Furthermore, non-tumor-bearing mice on caloric 
restriction demonstrated a higher mean body weight 
loss than tumor-bearing on caloric restriction.  This 
difference may in part, but not exclusively, be attributed 
to tumor weight. Increased organ weight, i.e. liver and 
spleen, has been reported in C26-bearing mice [45, 46] 
and is likely to have contributed to these difference in 
body weight. Moreover, considering fluid intake was 
not monitored a possible contribution of water weight is 
unknown. Lastly, despite energy intake being fixed, 
energy expenditure is not. Possible differences in phy-
sical activity may too have contributed to these 
differences. 
 
Studies employing caloric restriction have been 
primarily aimed at investigating its role in improving 
the efficacy of anti-cancer therapies [47-50], protecting 
against anti-cancer therapy side-effects [51, 52],  as well 
as preventing oncogenesis [48]. Although the difference 
in tumor mass was non-significant between the C26 TB 
DRI and C26 TB 30% CR mice in the current study, an 
earlier meta-analysis has shown that caloric restriction 
may reduce tumor growth. [53] This anti-cancer effect 
has also been described after short-term fasting and 
fasting cycles [54]. Even though in the current study we 
did not seek to investigate the anti-cancer effects of 
caloric restriction, the observed trend towards reduced 
tumor growth can be regarded as an additional benefit 
of caloric restriction.  
 
Several limitations apply to the present study. The study 
was powered on an expected reduction in loss of muscle 
weight. As such, non-significant differences in second-
dary outcome parameters (e.g. relative mRNA expres-
sion levels) may have been subject to type II errors. 
Furthermore, survival was not included as one of the 
endpoints due to the strict ethical guidelines associated 
with the initiation of this study. Another important 
consideration is timing of caloric restriction. For this 
study mice were put on a calorie restricted diet prior to 
inoculation of cancer cells. This may limit direct 
translation of these findings to clinical patients, who 
have established cancer, and may already suffer from 
anorexia Moreover, a recent study by Boldrin et al. 
reports that changes induced by caloric restriction in an 
age-related sarcopenia model do not persist with time, 
and, perhaps even more important, are dependent on 
mouse strain and gender differences [55]. Taking our 
own findings into account we concur with the authors of 
the aforementioned study to be cautious in applying 
caloric restriction to improve skeletal muscle function 
in humans. 
 
In conclusion, we found that caloric restriction limits 
the loss of muscle strength in vivo in an experimental 
cancer-associated cachexia model. Caloric restriction 
did not aggravate the loss of cachexia associated muscle 
mass despite significant body weight loss. These 
findings suggest that although caloric restriction does 
not fully protect against the detrimental effects of 
cancer-associated cachexia, it does limit muscle 
strength loss.  This suggests that caloric restriction 
might be safely utilized in improving the efficacy of-, 
and protect against the adverse side effects of anti-
cancer therapies. Further research is warranted to 
confirm these findings upon initiation of caloric 
restriction in early and late-stage cancer.  
 
MATERIALS AND METHODS 
 
Animal Ethics Committee approval 
 
All animal experiments were performed with the 
approval of the local Animal Ethics Committee and in 
accordance with the Dutch National Experiments on 
Animal Act and complied with the EU adopted 




Male CD2F1 (BALB/c × DBA/2 F1) mice of 8 weeks 
weighing approximately 25 grams were purchased from 
Charles River, Maastricht, the Netherlands. All mice 
were housed in individually ventilated cages under 
standard conditions with a 12 h light-dark cycle (n = 3 – 
4 animals per cage). Animals were acclimatized for one 




All animals had ad libitum access to water and CRM (P) 
chow (Special Diet Services, Witham, Essex, UK) 
during the acclimatization period and throughout the 
full duration of the experiment. At the start of the 
experiment dietary intake was determined in 3 cages 
that were randomly allocated as to become tumor-
bearing (TB). Twenty-four-hour food consumption in 
these cages was determined daily by weighing the 
remnant chow and calculating the difference from the 
preceding day. This was set as the dietary reference 
intake (DRI) [56]. The other cages were randomly 
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allocated as TB, 30% CR animals (i.e. chow weighing 
70% of the DRI); non-tumor bearing (NTB), 30% CR 
animals; and NTB, matched intake animals (i.e. chow 
weighing 100% of the DRI of the TB animals). All 
groups consisted of 10 mice. We did not include an AL-
NTB group to control for weight loss due to reduced 
food intake in the TB mice. The pair fed non tumor 
bearing control group we used compensates for the 
effects of possible reduced food intake by the tumor 
bearing animals which allows us to discriminate 
between the effects of reduced food intake per se, and 
the effects of the combination of the presence of a 
tumor and reduced food intake. 
 
Cancer cachexia model 
 
Colon-26 (C26) adenocarcinoma cells were kindly 
provided by Dr. D.O. McCarthy (Ohio State University, 
Columbus, OH, USA). These cells were cultured in 
RPMI 1640 (Westburg BV, Leusden, The Netherlands) 
supplemented with 10% fetal bovine serum (FBS, 
Sigma-Aldrich, St. Louis, The United States of 
America), and 1% penicillin/streptomycin (P/S, Fisher 
Scientific, Waltham, The United States of America) at 
37oC with 5% CO2. Animals allocated in TB groups 
received a subcutaneous inoculation in the right flank 
with 0.5 x 106 C26 adenocarcinoma cells in 100 μL 
sterile PBS on the 14th day of the experiment. The 
inoculation was done under anesthesia by isoflurane 
inhalation (5% isoflurane induction). This is a well-
established model of cancer cachexia in mice [57].  
 
Grip strength assessment 
 
Combined hind- and forelimb grip strength was 
measured twice per week by placing the animal on a 
grid attached to a force gauge (BIOSEB, Chaville, 
France), and steadily pulling the mice by the tail along 
the sensor axle until grip is released. The maximum 
strength produced before releasing the grid was 
registered in triplicate with one minute rest period for 
each animal. Obtained values were averaged to provide 
a mean force measurement for each individual animal 
and subsequently normalized to each animal’s grip-
strength respectively on day zero. 
 
Body weight, muscle mass, and tumor size 
 
Body weight was recorded daily. Tumor size was 
recorded every other day starting on day 23 of the 
experiment, i.e. day 9 after tumor inoculation, using 
digital calipers. Tumor mass was estimated via the 
formula mass (mg) = tumor volume (mm3) = width2 x 
length/2 [58]. Animals were sacrificed by cardiac 
puncture followed by cervical dislocation under iso-
flurane anesthesia on day 35 of the experiment, i.e. 21 
days after tumor inoculation. Immediately following 
sacrifice the gastrocnemius (GCM), and tibialis anterior 
(TA) muscles of both hind legs and tumor were dissect-
ted, weighed and immediately snap-frozen in liquid 
nitrogen and stored at -80 °C until analysis. 
 
RNA isolation and Real-time polymerase chain 
reaction 
 
For gene expression analysis, total RNA was isolated 
from snap-frozen GCM muscle tissue using Trizol 
reagent (Invitrogen, Breda, the Netherlands), and 
subsequently purified by DNase treatment (RQ1 RNase-
Free DNase) (Promega Benelux B.V., Leiden, the 
Netherlands). 1 μg of total RNA was reversed trans-
cribed to cDNA using random hexamer primers 
(Invitrogen, Breda, the Netherlands), and Superscript II 
RT (Invitrogen, Breda, the Netherlands). Quantitative 
real-time polymerase chain reaction (RT-PCR) was 
performed using an iCycler real-time PCR system 
(Biorad, California, The United States of America) 
using SYBR Green (Sigma-Aldrich, St. Louis, The 
United States of America). Used primer sequences can 
be found in Table 1. GAPDH was used as housekeeping 
gene for normalization. Relative gene expression was 
calculated (2^delta delta CT)/ (average 2^delta delta Ct 





Categorical data are expressed as number (percentage) 
and continuous variables as mean ± SEM (normal 
distribution, visually assessed and by means of the 
Shapiro-Wilks test). Body weight and grip-strength 
were normalized to each animal’s body weight and grip-
strength respectively on day 0. Muscle weight from the 
left hind leg and right hind leg were averaged to provide 
a mean GCM and TA muscle weight for each animal. 
Multiple group comparisons were done by one-way 
ANOVA with a Bonferroni’s post hoc test. For com-
parison between periodic measurements, the paired-
sample t-test was used. Statistical comparison between 
TB DRI and TB 30% CR mice in tumor weight was 
done by Student’s t-test. All analyses were performed 
using IBM SPSS Statistics for Windows, version 21.0 
(IBM Corp., Armonk, NY, USA). A P value < 0.05 was 
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